HER2 ADCs: GU Malignancies

CME

Emerging HER2-Targeted Antibody–Drug Conjugates in Genitourinary Malignancies

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: April 08, 2024

Expiration: October 07, 2024

Elizabeth R. Plimack
Elizabeth R. Plimack, MD, MS, FASCO

Activity

Progress
1
Course Completed

Introduction

In this activity, Elizabeth R. Plimack, MD, MS, FASCO, reviews recent developments in HER2 testing, appraises clinical trial results for anti-HER2 antibody–drug conjugate (ADC) therapy, and discusses current strategies on managing the safety profile of anti-HER2 ADCs for genitourinary (GU) cancers.  

Please note that the slide thumbnails in this activity link to a PowerPoint slideset that also can be found here. The slideset also may be downloaded by clicking on any of the thumbnails within the activity. 

Clinical Care Options intends to measure the educational impact of this activity. A few questions will be asked twice: Once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared. 

Before continuing with this educational activity, please take a moment to answer the following questions. 

For those providing patient care, how many patients with GU cancer (eg, bladder, kidney, penile) do you provide care for in a typical month?

Which of the following HER2 alterations is most frequently identified in patients with bladder cancer?

The phase II DESTINY-PanTumor02 trial evaluated trastuzumab deruxtecan (T-DXd) monotherapy in patients with advanced solid tumors not eligible for curative treatment and HER2+ expression. Which of the following efficacy results were reported for T-DXd in the GU patient population?